Acadia Healthcare Co (NASDAQ:ACHC) underwent analysis by 8 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 3 | 3 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 2 | 1 | 0 | 0 |
| 3M Ago | 1 | 1 | 1 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $85.62, a high estimate of $94.00, and a low estimate of $70.00. Highlighting a 9.87% decrease, the current average has fallen from the previous average price target of $95.00.
Exploring Analyst Ratings: An In-Depth Overview
The standing of Acadia Healthcare Co among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Sarah James | Cantor Fitzgerald | Maintains | Neutral | $90.00 | $90.00 |
| Ben Hendrix | RBC Capital | Maintains | Outperform | $94.00 | $94.00 |
| Gary Taylor | TD Cowen | Lowers | Buy | $91.00 | $101.00 |
| Andrew Mok | Barclays | Lowers | Overweight | $89.00 | $91.00 |
| Ann Hynes | Mizuho | Lowers | Neutral | $70.00 | $84.00 |
| Kevin Fischbeck | B of A Securities | Lowers | Buy | $90.00 | $105.00 |
| Andrew Mok | Barclays | Lowers | Overweight | $91.00 | $100.00 |
| Pito Chickering | Deutsche Bank | Maintains | Hold | $70.00 | - |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Acadia Healthcare Co. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Acadia Healthcare Co compared to the broader market.
- Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Acadia Healthcare Co's stock. This comparison reveals trends in analysts' expectations over time.
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Acadia Healthcare Co's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on Acadia Healthcare Co analyst ratings.
All You Need to Know About Acadia Healthcare Co
Acadia Healthcare Co Inc acquires and develops behavioral healthcare facilities in the United States, United Kingdom, and Puerto Rico. Acute inpatient psychiatric facilities and specialty treatment facilities contribute the vast majority of Acadia's revenue in the United States. The U.S. facilities receive the major proportion of payments from Medicaid, with the second-largest proportion from commercial payors. In the United Kingdom, the majority of Acadia's revenue comes from its healthcare facilities, and virtually all of the payment received is from the National Health Service.
A Deep Dive into Acadia Healthcare Co's Financials
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Acadia Healthcare Co's remarkable performance in 3 months is evident. As of 31 March, 2024, the company achieved an impressive revenue growth rate of 9.06%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Acadia Healthcare Co's net margin is impressive, surpassing industry averages. With a net margin of 9.95%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 2.7%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Acadia Healthcare Co's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.4% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Acadia Healthcare Co's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.69.
Analyst Ratings: Simplified
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.
This article was generated by Benzinga's automated content engine and reviewed by an editor.